How are CRMD strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CRMD strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 49.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$18.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a CRMD strangle?

The breakeven for the CRMD strangle priced on this page is roughly $6.82 and $8.18 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CRMD market-implied 1-standard-deviation expected move in the same options snapshot is approximately 14.25%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current CRMD implied volatility affect this strangle?

CRMD ATM IV is at 49.70% with IV rank near 8.31%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

CRMD Strangle Strategy

CRMD (CorMedix Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

CorMedix Inc. is a biopharmaceutical company engaged in the development and commercialization of medical treatments for the prevention and care of infectious and inflammatory conditions, serving markets both in the United States and internationally. Its leading product candidate, DefenCath/Neutrolin, represents a novel anti-infective solution. This treatment aims to diminish and avert catheter-related infections and blood clots in patients who utilize central venous catheters for medical procedures such as hemodialysis, total parenteral nutrition, and oncology care. Incorporated in 2006, the company initially operated as Picton Holding Company, Inc. until officially adopting the name CorMedix Inc. in January 2007. Its corporate headquarters are located in Berkeley Heights, New Jersey.

CRMD (CorMedix Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $557.0M, a trailing P/E of 3.12, a beta of 1.50 versus the broader market, a 52-week range of 6.13-14.96, average daily share volume of 1.2M, a public-listing history dating back to 2010, approximately 191 full-time employees. These structural characteristics shape how CRMD stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 1.50 indicates CRMD has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position. The trailing P/E of 3.12 is on the value side, where IV often compresses outside event windows because forward growth expectations are already discounted into the share price.

What is a strangle on CRMD?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

CRMD snapshot

As of August 14, 2026, spot at $7.50, ATM IV 49.70%, IV rank 8.31%, expected move 14.25%. The strangle on CRMD below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 7-day expiry.

Why this strangle structure on CRMD specifically: CRMD IV at 49.70% is on the cheap side of its 1-year range, which favors premium-buying structures like a CRMD strangle, with a market-implied 1-standard-deviation move of approximately 14.25% (roughly $1.07 on the underlying). The 7-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CRMD expiries trade a higher absolute premium for lower per-day decay. Position sizing on CRMD should anchor to the underlying notional of $7.50 per share and to the trader's directional view on CRMD stock.

CRMD strangle setup

The CRMD strangle below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CRMD at $7.50 on that close, the first option leg uses a $8.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CRMD chain at a 7-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CRMD shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$8.00	$0.10
Buy 1	Put	$7.00	$0.08

CRMD strangle risk and reward

Net Premium / Debit: -$18.00
Max Profit (per contract): Unbounded
Max Loss (per contract): -$18.00
Breakeven(s): $6.82, $8.18
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

CRMD strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on CRMD. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-99.9%	+$681.00
$1.67	-77.8%	+$515.28
$3.32	-55.7%	+$349.56
$4.98	-33.6%	+$183.84
$6.64	-11.5%	+$18.13
$8.30	+10.6%	+$11.59
$9.95	+32.7%	+$177.31
$11.61	+54.8%	+$343.03
$13.27	+76.9%	+$508.75
$14.92	+99.0%	+$674.47

When traders use strangle on CRMD

Strangles on CRMD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CRMD chain.

CRMD thesis for this strangle

The market-implied 1-standard-deviation range for CRMD extends from approximately $6.43 on the downside to $8.57 on the upside. A CRMD long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CRMD IV rank near 8.31% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on CRMD at 49.70%. As a Healthcare name, CRMD options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CRMD-specific events.

CRMD strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CRMD positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CRMD alongside the broader basket even when CRMD-specific fundamentals are unchanged. Always rebuild the position from current CRMD chain quotes before placing a trade.

Frequently asked questions

What is a strangle on CRMD?: A strangle on CRMD is the strangle strategy applied to CRMD (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CRMD stock at $7.50 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed CRMD chain strike and the premiums come straight from that session's bid/ask midpoint.
How are CRMD strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CRMD strangle priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 49.70%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$18.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a CRMD strangle?: The breakeven for the CRMD strangle priced on this page is roughly $6.82 and $8.18 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The CRMD market-implied 1-standard-deviation expected move in the same options snapshot is approximately 14.25%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on CRMD?: Strangles on CRMD are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CRMD chain.
How does current CRMD implied volatility affect this strangle?: CRMD ATM IV is at 49.70% with IV rank near 8.31%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.